AMGN
NEUTRAL
$351.85
Live
Amgen Inc. · NASDAQ
Target $350.55
(-0.4%)
$261.43
52W Range
$391.29
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 01, 2026
Market cap
$189.67B
P/E
24.71
ROE
106.1%
Profit margin
21.0%
Debt/Equity
6.4
Dividend yield
2.89%
AI Analysis
AI-powered fundamental assessment
Confidence
85%
AMGN shows neutral fundamentals based on deterministic rules. Financial strength is strong (F-Score 6/9). Mixed signals with both opportunities and risks present.
Key Strengths
Strong profitability (21.0% margin)
Strong ROE of 106.1%
Key Risks
Premium vs Graham Number ($71.75)
High debt burden with D/E of 6.40
AI Fair Value Estimate
Based on comprehensive analysis
$420.08
+19.4% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
54
Moderate
50
60
70
40
50
AI Verdict
AMGN shows neutral fundamentals based on deterministic rules. Financial strength is strong (F-Score 6/9). Mixed signals with both opportunities and risks present.
Key drivers: Strong profitability (21.0% margin), Strong ROE of 106.1%, Premium vs Graham Number ($71.75)
Confidence
55%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
- Trades above Graham Number.
Future
60/100
Rule-based growth outlook.
Positives
- Growth-implied value exceeds price.
Watchpoints
No urgent risks highlighted.
Past
70/100
Historical performance + price trend: Shares moved +65.2% over 5Y and +16.5% over 1Y.
Positives
- ROE sits at 106.1%.
- Healthy profit margin of 21.0%.
Watchpoints
No urgent risks highlighted.
Health
40/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
- High D/E ratio (6.40).
Dividend
50/100
Dividend policy fallback.
Positives
- Moderate dividend profile (Score: 50/100).
- Yield: 2.9%.
Watchpoints
No urgent risks highlighted.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$351.85
Analyst Target
$350.55
Upside/Downside
-0.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AMGN and closest competitors.
Updated 2026-03-31
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AMGN
Amgen Inc.
Primary
|
+65.2% | +59.9% | +16.5% | +26.4% | -8.8% | +1.0% |
|
TMO
Thermo Fisher Scientific Inc.
Peer
|
+6.7% | -9.7% | +18.7% | -9.2% | +7.5% | -3.3% |
|
ABT
Abbott Laboratories
Peer
|
-10.8% | +2.5% | -18.4% | -21.1% | -7.6% | -1.9% |
|
ISRG
Intuitive Surgical, Inc.
Peer
|
+56.7% | +55.1% | -0.6% | +1.6% | -2.6% | +1.4% |
|
GILD
Gilead Sciences, Inc.
Peer
|
+144.5% | +69.7% | +29.3% | +10.8% | -3.2% | -4.9% |
AMG
Amgen Inc.
Primary
5Y
+65.2%
3Y
+59.9%
1Y
+16.5%
6M
+26.4%
1M
-8.8%
1W
+1.0%
TMO
Thermo Fisher Scientific Inc.
Peer
5Y
+6.7%
3Y
-9.7%
1Y
+18.7%
6M
-9.2%
1M
+7.5%
1W
-3.3%
ABT
Abbott Laboratories
Peer
5Y
-10.8%
3Y
+2.5%
1Y
-18.4%
6M
-21.1%
1M
-7.6%
1W
-1.9%
ISR
Intuitive Surgical, Inc.
Peer
5Y
+56.7%
3Y
+55.1%
1Y
-0.6%
6M
+1.6%
1M
-2.6%
1W
+1.4%
GIL
Gilead Sciences, Inc.
Peer
5Y
+144.5%
3Y
+69.7%
1Y
+29.3%
6M
+10.8%
1M
-3.2%
1W
-4.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
24.71
Forward P/E
15.11
PEG Ratio
N/A
P/B Ratio
21.9
P/S Ratio
5.16
EV/Revenue
6.42
EV/EBITDA
14.2
Market Cap
$189.67B
Profitability
Profit margins and return metrics
Profit Margin
20.98%
Operating Margin
30.55%
Gross Margin
70.78%
ROE
106.1%
ROA
7.93%
Growth
Revenue and earnings growth rates
Revenue Growth
+8.6%
Earnings Growth
+112.1%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+112.6%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
6.4
High debt
Current Ratio
1.14
Good
Quick Ratio
0.73
Poor
Cash/Share
$16.93
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$9.9B
Gross Margin
69.8%
Op. Margin
27.6%
Net Margin
13.5%
Total Assets
$90.6B
Liabilities
$81.9B
Equity
$8.7B
Debt/Equity
9.46x
Operating CF
$1.6B
CapEx
$-0.6B
Free Cash Flow
$1.0B
FCF Yield
60%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-03
$5.29
+11.9% surprise
2025-11-04
$5.64
+12.5% surprise
2025-08-05
$2.65
-15.1% surprise
Healthcare Sector Comparison
Comparing AMGN against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
24.71
This Stock
vs
75.44
Sector Avg
-67.2%
(Discount)
Return on Equity (ROE)
106.1%
This Stock
vs
-88.14%
Sector Avg
-220.4%
(Below Avg)
Profit Margin
20.98%
This Stock
vs
-16.28%
Sector Avg
-228.9%
(Weaker)
Debt to Equity
6.4
This Stock
vs
2.66
Sector Avg
+140.5%
(Higher)
Revenue Growth
8.6%
This Stock
vs
124.04%
Sector Avg
-93.1%
(Slower)
Current Ratio
1.14
This Stock
vs
4.47
Sector Avg
-74.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AMGN
Amgen Inc.
|
NEUTRAL | $189.67B | 24.71 | 106.1% | 21.0% | $351.85 | |
|
TMO
Thermo Fisher Scientific Inc.
|
NEUTRAL | $191.01B | 28.99 | 13.0% | 15.0% | $513.98 | Compare |
|
ABT
Abbott Laboratories
|
NEUTRAL | $176.48B | 27.3 | 13.0% | 14.7% | $101.56 | Compare |
|
ISRG
Intuitive Surgical, Inc.
|
NEUTRAL | $165.37B | 59.16 | 16.7% | 28.4% | $465.6 | Compare |
|
GILD
Gilead Sciences, Inc.
|
NEUTRAL | $164.96B | 19.6 | 40.7% | 28.9% | $132.9 | Compare |
AMGN
Amgen Inc.
NEUTRAL
Mkt Cap
$189.7B
P/E
24.7
ROE
106.1%
Price
$351.85
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | BRADWAY ROBERT A | Chief Executive Officer | Option Exercise | 119,782 | $18,727,916 |
| 2026-03-03 | GRAHAM JONATHAN P | General Counsel | Stock Award | 10,723 | - |
| 2026-03-03 | GORDON MURDO | Officer | Stock Award | 13,403 | - |
| 2026-03-03 | BRADWAY ROBERT A | Chief Executive Officer | Stock Award | 42,657 | - |
| 2026-03-03 | GRIFFITH PETER H. | Chief Financial Officer | Stock Award | 12,063 | - |
| 2026-03-03 | GRYGIEL NANCY A | Officer | Stock Award | 2,010 | - |
| 2026-03-03 | KHOSLA RACHNA | Officer | Stock Award | 1,876 | - |
| 2026-03-03 | MILLER DEREK | Officer | Stock Award | 3,484 | - |
| 2026-03-03 | BUSCH MATTHEW C. | Officer | Stock Award | 938 | - |
| 2026-03-03 | REESE DAVID M. | Chief Technology Officer | Stock Award | 12,063 | - |
| 2026-03-03 | SANTOS ESTEBAN | Officer | Stock Award | 11,259 | - |
| 2026-02-26 | SANTOS ESTEBAN | Officer | Option Exercise | 54,792 | $9,270,143 |
| 2026-02-26 | SANTOS ESTEBAN | Officer | Sale | 54,792 | $20,772,595 |
| 2026-02-19 | BUSCH MATTHEW C. | Officer | Sale | 1,000 | $375,790 |
| 2025-11-20 | GRYGIEL NANCY A | Officer | Option Exercise | 3,139 | $532,691 |
BRADWAY ROBERT A
Chief Executive Officer
2026-03-04
119,782 shares
·
$18,727,916
GRAHAM JONATHAN P
General Counsel
2026-03-03
10,723 shares
GORDON MURDO
Officer
2026-03-03
13,403 shares
BRADWAY ROBERT A
Chief Executive Officer
2026-03-03
42,657 shares
GRIFFITH PETER H.
Chief Financial Officer
2026-03-03
12,063 shares
GRYGIEL NANCY A
Officer
2026-03-03
2,010 shares
KHOSLA RACHNA
Officer
2026-03-03
1,876 shares
MILLER DEREK
Officer
2026-03-03
3,484 shares
BUSCH MATTHEW C.
Officer
2026-03-03
938 shares
REESE DAVID M.
Chief Technology Officer
2026-03-03
12,063 shares
SANTOS ESTEBAN
Officer
2026-03-03
11,259 shares
SANTOS ESTEBAN
Officer
2026-02-26
54,792 shares
·
$9,270,143
SANTOS ESTEBAN
Officer
2026-02-26
54,792 shares
·
$20,772,595
BUSCH MATTHEW C.
Officer
2026-02-19
1,000 shares
·
$375,790
GRYGIEL NANCY A
Officer
2025-11-20
3,139 shares
·
$532,691
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
29 analysts
Jefferies
2026-03-10
Hold
Barclays
2026-02-20
Equal-Weight
Wells Fargo
2026-02-19
Equal-Weight
Equal-Weight
Piper Sandler
2026-02-18
Overweight
Overweight
Freedom Broker
2026-02-12
Buy
Hold
Argus Research
2026-02-06
Buy
Buy
Guggenheim
2026-02-06
Neutral
Neutral
Citigroup
2026-02-04
Neutral
Neutral
Morgan Stanley
2026-02-04
Equal-Weight
Equal-Weight
Cantor Fitzgerald
2026-02-04
Neutral
Neutral
Past News Coverage
Recent headlines mentioning AMGN from our newsroom.
Newest → oldest
No matching news yet.